

CURRENT REPORT 7/2024

February 5, 2024

Achievement of the second milestone under license agreement with Exelixis Inc.

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Ryvu", "Company"), announces that on February 3, 2024 the Company has received a notice that the second milestone has been achieved in the research collaboration with Exelixis Inc. with its registered office in Alameda, California ("Exelixis") under the license agreement, which was reported by the Company in current report 11/2022 dated July 7, 2022 (the "Agreement"). The purpose of the Agreement is to develop novel targeted therapies using the STING (STimulator of INterferon Genes) technology developed by Ryvu.

Based on the achievement of the milestone, Ryvu is entitled to receive a payment of USD 2 million (PLN 7 928 200 converted at the average exchange rate of the National Bank of Poland on February 2, 2024, 1 USD = 3.9641 PLN).

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka - Vice-President of the Management Board